Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,899.60
(
0.11%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
94.14
(
-0.92%
)
Bitcoin
77,521.05
(
1.56%
)
News Focus
News Focus
Post# of 257433
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 188477

Wednesday, 03/11/2015 8:09:30 PM

Wednesday, March 11, 2015 8:09:30 PM

Post# of 257433
OCRX CC—One sell-side analyst asked a surprisingly good question: If the IV formulation of OCR_002 does not work out for the acute HE setting, would OCRX still develop the oral formulation of OCR-002 for the post-discharge market? The answer was yes.

OCRX plans to start a phase-1 trial for the oral formulation in 2H15.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today